medroxyprogesterone acetate has been researched along with Atypical Endometrial Hyperplasia in 79 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (10.13) | 18.7374 |
| 1990's | 12 (15.19) | 18.2507 |
| 2000's | 21 (26.58) | 29.6817 |
| 2010's | 28 (35.44) | 24.3611 |
| 2020's | 10 (12.66) | 2.80 |
| Authors | Studies |
|---|---|
| Campo, G; Candiani, M; Giardina, P; Pagliardini, L; Papaleo, E; Patruno, C; Rebecchi, A; Vanni, VS | 1 |
| Aoki, D; Banno, K; Chiyoda, T; Hirano, T; Makabe, T; Sakai, K; Takahashi, M; Yamagami, W; Yoshimura, T | 1 |
| Buca, D; D'Antonio, F; De Rocco, S; Dessole, M; Fanfani, F; Leombroni, M; Liberati, M; Lucidi, A; Nappi, L; Oronzii, L; Petrillo, M; Scambia, G | 1 |
| Fukuma, Y; Hamuro, A; Hasegawa, K; Ikenoue, S; Kasuga, Y; Ochiai, D; Oishi, M; Tamai, J; Tanaka, M; Tanaka, Y; Yamagami, W; Yoshimura, T | 1 |
| Eguchi, S; Ga, H; Honjoh, H; Miyamoto, Y; Mori, M; Nishijima, A; Osuga, Y; Sone, K; Taguchi, A | 1 |
| de Gregorio, N; Dimpfl, M; Janni, W; Schäffler, H; Schochter, F | 1 |
| Fujiwara, T; Hanaoka, H; Hori, M; Kawasaki, Y; Mitsuhashi, A; Shozu, M | 1 |
| Bertozzi, S; Biasioli, A; Cagnacci, A; Londero, AP; Mangino, FP; Mariuzzi, L; Orsaria, M; Scrimin, F | 1 |
| He, Y; Wang, J; Wang, Y; Zhou, R | 1 |
| Cho, A; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Park, JY; Suh, DS | 1 |
| Acmaz, G; Akkaya, H; Cagli, F; Karakilic, EU; Madendag, I; Madendag, Y; Uysal, G | 1 |
| Kajiyama, H; Kikkawa, F; Mizuno, M; Niimi, K; Sakata, J; Shibata, K; Suzuki, S; Tamauchi, S; Utsumi, F | 1 |
| Erdenebaatar, C; Honda, R; Katabuchi, H; Monsur, M; Ohba, T; Saito, F; Tashiro, H; Yamaguchi, M | 1 |
| Aoki, D; Banno, K; Hirasawa, A; Kataoka, F; Makabe, T; Nomura, H; Sakai, K; Susumu, N; Yamagami, W | 1 |
| Demir Karakilic, I; Guler, I; Karabacak, N; Karabacak, O; Korucuoglu, U | 1 |
| Baloglu, A; Boz, A; Dolapcioglu, K | 1 |
| Chiti, Z; Dehghani, A; Dehghani-Firoozabadi, R; Dehghani-Firoozabadi, Z; Karimi-Zarchi, M; Miratashi-Yazdi, A; Tabatabaie, A; Teimoori, S | 1 |
| Archer, DF; Chines, AA; Harvey, JA; Lindsay, R; Mirkin, S; Pan, K; Pinkerton, JV | 1 |
| Clarke, BA; Feigenberg, T; Ferguson, SE; Gien, LT; Ismiil, N; Laframboise, S; Massey, C; Simpson, AN | 1 |
| Dehghani, A; Dehghani-Tafti, M; Karimi Zarchi, M; Miratashi-Yazdi, A; Tabatabaie, A; Teimoori, S | 1 |
| Iwasaku, K; Kataoka, H; Kitawaki, J; Kuroboshi, H; Mori, T; Sawada, M; Tatsumi, H; Yamamoto, T | 1 |
| Arnes, M; Hvingel, B; Orbo, A | 1 |
| Ankarali, H; Caglar, M; Mesci-Haftaci, S; Yavuzcan, A | 1 |
| Aki, I; Fujita, M; Kimura, T; Kobayashi, E; Mabuchi, S; Ohyagi-Hara, C; Sawada, K; Tsutsui, T; Ueda, Y; Yoshino, K | 1 |
| Bai, Y; Guo, Q; Li, C; Li, M; Wang, C; Yan, L; Zhang, H; Zhao, X | 1 |
| Diamond, K; Nickkho-Amiry, M; Seif, MW | 1 |
| Li, Y; Sun, X; Wang, J; Wang, Y; Zhang, H | 1 |
| Emarh, M | 1 |
| Bai, Y; Gao, Y; Li, C; Li, M; Yan, L; Zhang, H; Zhang, L; Zhao, M; Zhao, X | 1 |
| Bi, Y; Chen, M; Jin, Y; Li, Y; Pan, L; Shan, Y | 1 |
| Hanaoka, H; Kiyokawa, T; Koshizaka, M; Mitsuhashi, A; Sato, Y; Shozu, M | 1 |
| Arnes, M; Straume, B; Vereide, AB; Ørbo, A | 1 |
| Abdel-Raouf, SM; Abdeldayem, HM; Arafa, EM; Atwa, K; Girbash, EF; Nooh, AM | 1 |
| Cândido, EB; Carneiro, MM; Carvalho-Macedo, AC; Lara, AC; Rocha, AL; Silva-Filho, AL; Vidigal, PV | 1 |
| Arnes, M; Borgfeldt, C; Lyså, LM; Straume, B; Ørbo, A | 1 |
| Ahn, HS; Kim, HJ; Lee, JH; Park, WI; Song, JY; Yuk, JS | 1 |
| Arnes, M; Hancke, C; Larsen, K; Pettersen, I; Vereide, AB; Ørbo, A | 1 |
| Gumen, A; Keskin, A; Ozyigit, MO; Yilmaz, R; Yilmazbas, G | 1 |
| Han, AR; Kim, DY; Kim, JH; Kim, YM; Kim, YT; Kwon, YS; Nam, JH | 1 |
| Akgul, MA; Bozkurt, U; Haberal, A; Kayikcioglu, F; Ozdegirmenci, O | 1 |
| Chines, AA; Komm, BS; Mirkin, S; Pan, K | 1 |
| Fujita, K; Kase, H; Kurabayashi, T; Sugaya, S; Suzuki, M; Tanaka, K | 1 |
| Binder, EF; Bronder, DR; Kohrt, WM; Pinto, AB; Williams, DB | 1 |
| Cunnane, MF; Pickar, JH; Speroff, L; Wheeler, JE; Yeh, IT | 1 |
| Itoh, J; Kajiwara, H; Matsui, N; Miyamoto, T; Murakami, M; Osamura, RY; Shinozuka, T; Yasuda, M | 1 |
| Kim, KS; Kim, O | 1 |
| Eren, S; Pekin, O; Tugrul, S; Uslu, H; Yildirim, G | 1 |
| Arnes, M; Kaino, T; Sager, G; Vereide, AB; Ørbo, A | 1 |
| Fujiwara, T; Horie, K; Kugu, K; Minaguchi, T; Nakagawa, S; Nei, T; Osuga, Y; Takazawa, Y; Taketani, Y; Yano, T; Yasugi, T; Yoshikawa, H | 1 |
| Bhatti, SF; Coryn, M; Ducatelle, R; Duchateau, L; Kooistra, HS; Mol, JA; Okkens, AC; Rao, NA; Rijnberk, A; Tshamala, M; van den Ingh, TS; Van Ham, LM | 1 |
| Archer, DF; den Hollander, W; Ferenczy, A; Gallagher, JC; Helmond, FA; Hendrix, S; Rymer, J; Skouby, S; Stathopoulos, V | 1 |
| Castaneda, TA; Gambrell, RD; Massey, FM; Ricci, CA; Ugenas, AJ; Wright, JM | 1 |
| Cleary, RE; Ehrlich, CE; Young, PC | 1 |
| Granfors, E; Heikkinen, J; Hirvonen, E; Hulkko, S; Mäkäräinen, L; Nummi, S; Pekonen, F; Puolakka, J; Rautio, AM; Salmi, T | 1 |
| Badokhon, NH; Fujii, S; Konishi, I; Masuzawa, H; Nakayama, K; Nikaido, T | 1 |
| Fu, YS; Judd, HL; Schoenfeld, MJ; Voigt, BJ; Williams, DB | 1 |
| Pickar, JH; Woodruff, JD | 1 |
| Boyd, ME; Colgan, TJ; Ferenczy, A; Fugere, P; Lorrain, J; Ross, AH | 1 |
| Bukovsky, I; Hadas, E; Halperin, R; Maymon, R; Schneider, D | 1 |
| Kirpensteijn, J; Kooistra, HS; Mol, JA; Okkens, AC; Rijnberk, A; van Garderen, E | 1 |
| Abulafia, O; Adcock, JT; Sherer, DM; Triest, WE | 1 |
| Amezcua, CA; Felix, JC; Lu, JJ; Stanczyk, FZ; Zheng, W | 1 |
| Järvelä, I; Jouppila, P; Santala, M; Tekay, A | 1 |
| Isacson, C; New, MI; Newfield, RS; Spitz, IM | 1 |
| Fukunaga, M; Hataeg, M; Hiura, M; Iwasaka, T; Kaku, T; Kamura, T; Kodama, S; Kuwabara, Y; Kuzuya, K; Miyazaki, K; Nakano, H; Nishimura, T; Sakamoto, A; Sato, S; Tsuda, H; Yoshikawa, H | 1 |
| Gibbons, WE; Thorneycroft, IH | 1 |
| Cunnane, MF; Pickar, JH; Speroff, L; Wheeler, JE; Yeh, I | 1 |
| Charkviani, L; Charkviani, T; Kobiashvili, H | 1 |
| Imai, M; Jobo, T; Kawaguchi, M; Kuramoto, H | 1 |
| Dhaliwal, GK; England, GC; Noakes, DE | 1 |
| Baracchini, P; Bernardini, L; de Cecco, L; Ferraiolo, A; Fulcheri, E; Gerbaldo, D; Pescetto, G | 1 |
| Hando, T; Kurose, T; Motizuki, M; Ohmori, M; Sasagawa, M; Sasaki, T; Tanaka, K; Yamazaki, T; Yasuda, M | 1 |
| Gimes, G; Hidvégi, J; Szarvas, Z; Zsolnai, B | 1 |
| Allemann, J; Czernobilsky, B; Dallenbach-Hellweg, G | 1 |
| Griesinger, R; Schindler, AE | 1 |
| Dallenbach-Hellweg, G | 1 |
| Contreras Ortiz, O; Sananes, CE | 1 |
9 review(s) available for medroxyprogesterone acetate and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
Reproductive and pregnancy outcomes of fertility-sparing treatments for early-stage endometrial cancer or atypical hyperplasia: A systematic review and meta-analysis.
Topics: Abortion, Spontaneous; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hyperplasia; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Precancerous Conditions; Pregnancy; Pregnancy Outcome | 2022 |
Curative Polyendocrine Therapy in a 21-year-Old Patient with Endometrial Carcinoma: Case Report and Review of the Literature.
Topics: Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Retrospective Studies; Young Adult | 2023 |
Atypical polypoid adenomyoma follow-up and management: Systematic review of case reports and series and meta-analysis.
Topics: Adenomyoma; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Conservative Treatment; Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Pregnancy; Pregnancy Rate; Uterine Neoplasms | 2020 |
Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysterectomy; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Pregnancy; Retrospective Studies; Treatment Outcome; Young Adult | 2015 |
Obesity and menstrual disorders.
Topics: Amenorrhea; Contraceptive Agents, Female; Contraceptives, Oral, Combined; Endometrial Ablation Techniques; Endometrial Hyperplasia; Estrogens; Female; Humans; Hysterectomy; Intrauterine Devices, Medicated; Medroxyprogesterone Acetate; Menorrhagia; Menstruation Disturbances; Obesity; Oligomenorrhea; Prevalence; Progestins | 2015 |
Levonorgestrel-Releasing Intrauterine Systems Versus Oral Cyclic Medroxyprogesterone Acetate in Endometrial Hyperplasia Therapy: A Meta-Analysis.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Randomized Controlled Trials as Topic | 2017 |
Protecting the endometrium. Opposing the hyperplasia/malignancy potential of ERT.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Progesterone; Progesterone Congeners; Risk Factors | 1999 |
Cystic endometrial hyperplasia/pyometra in dogs: a review of the causes and pathogenesis.
Topics: Animals; Bacterial Infections; Biopsy; Dog Diseases; Dogs; Endometrial Hyperplasia; Female; Medroxyprogesterone Acetate; Metestrus; Progesterone; Progesterone Congeners; Receptors, Estrogen; Receptors, Progesterone; Uterine Diseases; Uterus | 2001 |
[Conservative organ-preserving measures in precancerous stages of endometrial cancer].
Topics: Adult; Endometrial Hyperplasia; Female; Humans; Hysterectomy; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Precancerous Conditions; Uterine Neoplasms | 1988 |
28 trial(s) available for medroxyprogesterone acetate and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
Medroxyprogesterone acetate plus metformin for fertility-sparing treatment of atypical endometrial hyperplasia and endometrial carcinoma: trial protocol for a prospective, randomised, open, blinded-endpoint design, dose-response trial (FELICIA trial).
Topics: Adult; Antineoplastic Agents, Hormonal; Clinical Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Follow-Up Studies; Humans; Hypoglycemic Agents; Medroxyprogesterone Acetate; Metformin; Proportional Hazards Models; Prospective Studies; Single-Blind Method; Treatment Outcome | 2020 |
The Efficacy of Dienogest in the Treatment of Simple Endometrial Hyperplasia without Atypia.
Topics: Adult; Endometrial Hyperplasia; Female; Hormone Antagonists; Humans; Medroxyprogesterone Acetate; Middle Aged; Nandrolone; Outcome Assessment, Health Care; Premenopause; Progesterone; Progestins; Prospective Studies | 2018 |
Gonadotropin-Releasing Hormone Analog Combined with Depot Medroxyprogesterone Acetate in the Management of Endometrial Hyperplasia A Prospective Randomized Clinical Study.
Topics: Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrium; Female; Gonadotropin-Releasing Hormone; Humans; Medroxyprogesterone Acetate; Menstruation; Prospective Studies | 2016 |
The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study.
Topics: Administration, Oral; Adult; Contraceptive Agents, Female; Endometrial Hyperplasia; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Patient Selection; Progestins; Prospective Studies; Treatment Failure | 2013 |
A comparison of the effect of levonorgestrel IUD with oral medroxyprogesterone acetate on abnormal uterine bleeding with simple endometrial hyperplasia and fertility preservation.
Topics: Administration, Oral; Adult; Contraceptive Agents, Female; Endometrial Hyperplasia; Female; Fertility Preservation; Humans; Intrauterine Devices; Levonorgestrel; Medroxyprogesterone Acetate; Metrorrhagia; Middle Aged; Ultrasonography; Young Adult | 2013 |
Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Topics: Adult; Aged; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrium; Estrogens, Conjugated (USP); Female; Humans; Indoles; Lumbar Vertebrae; Medroxyprogesterone Acetate; Middle Aged; Selective Estrogen Receptor Modulators; Treatment Outcome | 2014 |
Comparing letrozole with medroxyprogesterone acetate (MPA) as hormonal therapy for simple endometrial hyperplasia without atypia in adult and middle-aged women.
Topics: Adult; Antineoplastic Agents, Hormonal; Biopsy; Curettage; Dizziness; Endometrial Hyperplasia; Estradiol; Female; Fertility Preservation; Headache; Humans; Letrozole; Medroxyprogesterone Acetate; Middle Aged; Nitriles; Triazoles; Young Adult | 2013 |
Cyclic versus continuous medroxyprogesterone acetate for treatment of endometrial hyperplasia without atypia: a 2-year observational study.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; Biopsy; Endometrial Hyperplasia; Endometrium; Female; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Premenopause; Prospective Studies; Treatment Outcome; Young Adult | 2015 |
Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility; Fertility Preservation; Humans; Insulin Resistance; Medroxyprogesterone Acetate; Metformin; Neoplasm Recurrence, Local; Prospective Studies; Treatment Outcome; Young Adult | 2016 |
Relapse risk of endometrial hyperplasia after treatment with the levonorgestrel-impregnated intrauterine system or oral progestogens.
Topics: Administration, Oral; Adult; Antineoplastic Agents, Hormonal; Contraceptive Agents, Female; Endometrial Hyperplasia; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Recurrence | 2016 |
Depo-Provera Versus Norethisterone Acetate in Management of Endometrial Hyperplasia Without Atypia.
Topics: Administration, Oral; Adult; Contraceptive Agents, Female; Disease Management; Endometrial Hyperplasia; Female; Humans; Injections, Intramuscular; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Prospective Studies | 2016 |
HE4 is a novel tissue marker for therapy response and progestin resistance in medium- and low-risk endometrial hyperplasia.
Topics: Biomarkers; Biopsy; Dose-Response Relationship, Drug; Drug Resistance; Endometrial Hyperplasia; Endometrium; Female; Gene Expression Regulation; Humans; Inclusion Bodies; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Precancerous Conditions; Proteins; Risk; Treatment Outcome; WAP Four-Disulfide Core Domain Protein 2 | 2016 |
Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia.
Topics: Adult; Endometrial Hyperplasia; Female; Humans; Lynestrenol; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Progestins; Prospective Studies; Treatment Outcome | 2011 |
Effects of bazedoxifene/conjugated estrogens on endometrial safety and bone in postmenopausal women.
Topics: Adult; Bone Density; Bone Density Conservation Agents; Double-Blind Method; Endometrial Hyperplasia; Estrogens, Conjugated (USP); Female; Humans; Indoles; Medroxyprogesterone Acetate; Middle Aged; Osteoporosis, Postmenopausal; Placebos; Postmenopause; Selective Estrogen Receptor Modulators | 2013 |
Effects of trimonthly progestin administration on the endometrium in elderly postmenopausal women who receive hormone replacement therapy: a pilot study.
Topics: Aged; Biopsy; Double-Blind Method; Endometrial Hyperplasia; Endometrium; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Pilot Projects; Placebos; Postmenopause; Progesterone Congeners; Prospective Studies; Ultrasonography; Uterine Hemorrhage | 2003 |
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results.
Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endometrial Hyperplasia; Estrogen Replacement Therapy; Estrogens; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Placebos | 2003 |
Effects of two different regimens of continuous hormone replacement therapy on endometrial histopathology and postmenopausal uterine bleeding.
Topics: Adult; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Postmenopause; Time Factors; Uterine Hemorrhage | 2006 |
Endometrial effects of tibolone.
Topics: Aged; Carcinoma; Cohort Studies; Double-Blind Method; Drug Combinations; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norpregnenes; Pain; Uterine Hemorrhage | 2007 |
Can progestin be limited to every third month only in postmenopausal women taking estrogen?
Topics: Adult; Aged; Climacteric; Drug Administration Schedule; Endometrial Hyperplasia; Estradiol; Estrogen Replacement Therapy; Female; Humans; Medroxyprogesterone Acetate; Menstruation Disturbances; Middle Aged; Patient Satisfaction; Postmenopause; Prospective Studies; Treatment Outcome; Weight Gain | 1995 |
Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
Topics: Aged; Cholesterol, HDL; Double-Blind Method; Drug Administration Schedule; Endometrial Hyperplasia; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Fibrinogen; Glucose; Heart Diseases; Humans; Insulin; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Risk Factors; Systole; Weight Gain | 1995 |
Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias.
Topics: Adult; Aged; Endometrial Hyperplasia; Endometrium; Female; Humans; Immunoenzyme Techniques; Medroxyprogesterone Acetate; Menstrual Cycle; Middle Aged; Receptors, Estrogen; Receptors, Progesterone | 1994 |
Assessment of less than monthly progestin therapy in postmenopausal women given estrogen replacement.
Topics: Adult; Aged; Cholesterol; Endometrial Hyperplasia; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Triglycerides; Uterine Hemorrhage | 1994 |
Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The Menopause Study Group.
Topics: Aged; Double-Blind Method; Drug Therapy, Combination; Endometrial Hyperplasia; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged; Prospective Studies | 1994 |
Comparison of transdermal and oral sequential gestagen in combination with transdermal estradiol: effects on bleeding patterns and endometrial histology.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Biopsy; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrium; Estradiol; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Norethindrone; Norethindrone Acetate; Progesterone Congeners; Prospective Studies; Uterine Hemorrhage | 1993 |
Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
Topics: Biopsy; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estrogen Replacement Therapy; Estrogens; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Postmenopause; Progesterone; Progesterone Congeners; Progestins | 1996 |
Thermal balloon endometrial ablation therapy induces a rise in uterine blood flow impedance: a randomized prospective color Doppler study.
Topics: Catheter Ablation; Catheterization; Endometrial Hyperplasia; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Menorrhagia; Postmenopause; Premenopause; Progesterone Congeners; Time Factors; Ultrasonography, Doppler, Color; Uterus | 2001 |
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate.
Topics: Adult; Aging; Animals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Endometrial Hyperplasia; Endometrium; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Horses; Humans; Incidence; Medroxyprogesterone Acetate; Middle Aged | 2001 |
Endometrial response in sequential cyclic therapy assessed with associated hysteroscopy and histology.
Topics: Adult; Atrophy; Endometrial Hyperplasia; Endometrium; Estradiol; Estrogen Replacement Therapy; Estrogens, Conjugated (USP); Female; Humans; Hysteroscopy; Medroxyprogesterone Acetate; Middle Aged | 1992 |
42 other study(ies) available for medroxyprogesterone acetate and Atypical Endometrial Hyperplasia
| Article | Year |
|---|---|
Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia.
Topics: Abortion, Spontaneous; Adult; Cohort Studies; Endometrial Hyperplasia; Female; Humans; Infertility, Female; Intrauterine Devices, Medicated; Levonorgestrel; Live Birth; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Rate; Prospective Studies; Reproductive Techniques, Assisted; Treatment Outcome | 2021 |
Clinical Usefulness of Endometrial Cytology in Determining the Therapeutic Effect of Fertility Preserving Therapy.
Topics: Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility; Humans; Medroxyprogesterone Acetate; Retrospective Studies | 2022 |
Obstetric outcomes after medroxyprogesterone acetate treatment for early stage endometrial cancer or atypical endometrial hyperplasia: a single hospital-based study.
Topics: Adult; Dilatation and Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Hospitals; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Obstetrics; Placenta Accreta; Pregnancy; Premature Birth; Retrospective Studies | 2023 |
Prognosis of patients with endometrial cancer or atypical endometrial hyperplasia after complete remission with fertility-sparing therapy.
Topics: Child; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Pregnancy; Prognosis; Retrospective Studies; Treatment Outcome | 2023 |
Oncologic and obstetrical outcomes after fertility-preserving retreatment in patients with recurrent atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Gonadotropin-Releasing Hormone; Humans; Levonorgestrel; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Pregnancy; Pregnancy Outcome; Retreatment; Retrospective Studies; Young Adult | 2020 |
Continued medical treatment for persistent early endometrial cancer in young women.
Topics: Administration, Oral; Antineoplastic Agents, Hormonal; Biopsy; Carcinoma, Endometrioid; Disease-Free Survival; Drug Administration Schedule; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Fertility Preservation; Follow-Up Studies; Humans; Intrauterine Devices; Levonorgestrel; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Megestrol Acetate; Myometrium; Neoplasm Grading; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Prognosis; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome; Ultrasonography | 2021 |
Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Medroxyprogesterone Acetate; Neoplasm Recurrence, Local; Outcome Assessment, Health Care; Recurrence | 2018 |
Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate.
Topics: Adult; Antineoplastic Agents, Hormonal; Cabergoline; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hyperprolactinemia; Lectins, C-Type; Medroxyprogesterone Acetate; Retrospective Studies; Young Adult | 2018 |
Is repeated high-dose medroxyprogesterone acetate (MPA) therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Recurrence, Local; Pregnancy | 2018 |
Fertility sparing treatment of complex atypical hyperplasia and low grade endometrial cancer using oral progestin.
Topics: Adult; Antineoplastic Agents, Hormonal; Carcinoma, Endometrioid; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Humans; Hysterectomy; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Grading; Organ Sparing Treatments; Pregnancy; Pregnancy Outcome; Pregnancy Rate; Reproductive Techniques, Assisted; Retrospective Studies; Treatment Outcome | 2014 |
Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women.
Topics: Adult; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility Preservation; Forkhead Box Protein O1; Forkhead Transcription Factors; Humans; Immunohistochemistry; Japan; Medroxyprogesterone Acetate; Organ Sparing Treatments; Receptors, Progesterone; Treatment Outcome | 2014 |
Levonorgestrel-impregnated Intrauterine device reduces occurrence of hyperplastic polyps: a population-based follow-up cohort study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Cohort Studies; Contraceptive Agents, Female; Endometrial Hyperplasia; Female; Follow-Up Studies; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Polyps; Uterine Diseases | 2014 |
Endometrial curettage in abnormal uterine bleeding and efficacy of progestins for control in cases of hyperplasia.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Female; Humans; Medroxyprogesterone Acetate; Middle Aged; Treatment Outcome; Uterine Hemorrhage; Young Adult | 2014 |
Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia.
Topics: Antineoplastic Agents, Hormonal; Biomarkers; Cell Line, Tumor; Drug Resistance, Neoplasm; Dual Specificity Phosphatase 6; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Precancerous Conditions; Progestins; Treatment Outcome; Up-Regulation | 2015 |
MPA influences tumor cell proliferation, migration, and invasion induced by RANKL through PRB involving the MAPK pathway in endometrial cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Cell Line, Tumor; Cell Movement; Cell Proliferation; Endometrial Hyperplasia; Female; Humans; MAP Kinase Signaling System; Medroxyprogesterone Acetate; Mice; Neoplasm Invasiveness; RANK Ligand; Receptors, Progesterone; Xenograft Model Antitumor Assays | 2015 |
SPAG9 May Be a Potential Prognostic Marker of Endometrial Hyperplasia and Grade 1 Endometrioid Adenocarcinoma Treated with Progestin.
Topics: Adaptor Proteins, Signal Transducing; Adult; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Blotting, Western; Carcinoma, Endometrioid; Cell Line, Tumor; Early Detection of Cancer; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Prognosis; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction | 2016 |
Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
Topics: Adult; Antineoplastic Agents, Hormonal; China; Disease-Free Survival; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Fertility Preservation; Humans; Medroxyprogesterone Acetate; Megestrol Acetate; Neoplasm Recurrence, Local; Obesity; Pregnancy; Progestins; Recurrence; Retrospective Studies; Treatment Outcome; Young Adult | 2016 |
Effect of letrozole in carcinogen-plus-estrogen-induced endometrial hyperplasia in mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinogenesis; Endometrial Hyperplasia; Endometrial Neoplasms; Endometrium; Estradiol; Ethylnitrosourea; Female; Letrozole; Medroxyprogesterone Acetate; Mice, Inbred BALB C; Nitriles; Progesterone; Reproducibility of Results; Time Factors; Treatment Outcome; Triazoles | 2016 |
Treatment results of endometrial hyperplasia after prospective D-score classification: a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Algorithms; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Female; Follow-Up Studies; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Observation; Risk Factors | 2008 |
Pathological abnormalities after long-term administration of medroxyprogesterone acetate in a queen.
Topics: Adenocarcinoma, Papillary; Animals; Cat Diseases; Cats; Contraceptive Agents, Female; Endometrial Hyperplasia; Female; Hysterectomy; Mammary Neoplasms, Animal; Medroxyprogesterone Acetate; Ovariectomy; Pyometra; Ultrasonography | 2009 |
Pregnancy outcomes using assisted reproductive technology after fertility-preserving therapy in patients with endometrial adenocarcinoma or atypical complex hyperplasia.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Dilatation and Curettage; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Infertility, Female; Medroxyprogesterone Acetate; Megestrol Acetate; Pregnancy; Pregnancy Outcome; Reproductive Techniques, Assisted; Retrospective Studies | 2009 |
Endometrial abnormalities in infertile women.
Topics: Adult; Carcinoma; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Infertility, Female; Medroxyprogesterone Acetate; Pregnancy; Pregnancy Rate; Progesterone Congeners; Prognosis; Reproductive Techniques, Assisted; Retrospective Studies | 2003 |
Malignant transformation of atypical endometrial hyperplasia after progesterone therapy showing germ-cell tumor-like differentiation.
Topics: Adenocarcinoma; Adult; Alkaline Phosphatase; alpha-Fetoproteins; Biomarkers, Tumor; Cell Transformation, Neoplastic; Chorionic Gonadotropin; Endometrial Hyperplasia; Endometrial Neoplasms; Fatal Outcome; Female; Germinoma; GPI-Linked Proteins; Humans; Hysterectomy; Immunoenzyme Techniques; Isoenzymes; Loss of Heterozygosity; Medroxyprogesterone Acetate; Microsatellite Repeats | 2004 |
Cystic endometrial hyperplasia and endometritis in a dog following prolonged treatment of medroxyprogesterone acetate.
Topics: Animals; Contraceptive Agents, Female; Dog Diseases; Dogs; Endometrial Hyperplasia; Endometritis; Female; Medroxyprogesterone Acetate | 2005 |
Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia.
Topics: Adult; Endometrial Hyperplasia; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Humans; Intrauterine Devices, Medicated; Levonorgestrel; Medroxyprogesterone Acetate; Middle Aged; Receptors, Progesterone; Stromal Cells | 2006 |
Combined phospho-Akt and PTEN expressions associated with post-treatment hysterectomy after conservative progestin therapy in complex atypical hyperplasia and stage Ia, G1 adenocarcinoma of the endometrium.
Topics: Adenocarcinoma; Administration, Oral; Adult; Combined Modality Therapy; Contraceptive Agents, Female; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Hysterectomy; Immunohistochemistry; Medroxyprogesterone Acetate; Middle Aged; Neoplasm Staging; Phosphorylation; Pregnancy; Progestins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Receptors, Estrogen; Receptors, Progesterone; Time Factors; Treatment Outcome; Tumor Suppressor Protein p53 | 2007 |
Role of progestin-induced mammary-derived growth hormone in the pathogenesis of cystic endometrial hyperplasia in the bitch.
Topics: Animals; Dog Diseases; Dogs; Endometrial Hyperplasia; Female; Gene Expression; Growth Hormone; Immunohistochemistry; Insulin-Like Growth Factor I; Mammary Glands, Animal; Medroxyprogesterone Acetate; Progesterone; Random Allocation; Receptors, Progesterone; Receptors, Somatotropin; Reverse Transcriptase Polymerase Chain Reaction; Uterus | 2007 |
Use of the progestogen challenge test to reduce the risk of endometrial cancer.
Topics: Adenocarcinoma; Aged; Endometrial Hyperplasia; Estrogens; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menopause; Middle Aged; Norethindrone; Norethindrone Acetate; Precancerous Conditions; Progesterone; Prospective Studies; Risk; Uterine Neoplasms | 1980 |
Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: therapeutic implications.
Topics: Adenocarcinoma; Endometrial Hyperplasia; Endometrium; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Megestrol; Receptors, Estrogen; Receptors, Progesterone; Uterine Neoplasms | 1981 |
Low levels of human decidua-associated protein 200 in uterine fluid reflect pathological conditions of the endometrium.
Topics: Adult; Aged; Body Fluids; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Humans; Immunoglobulins; Medroxyprogesterone Acetate; Menstruation; Middle Aged; Neoplasm Staging; Postmenopause; Pregnancy Proteins; Uterus | 1997 |
Lack of association of progestin-induced cystic endometrial hyperplasia with GH gene expression in the canine uterus.
Topics: Animals; Cysts; Cytoplasm; Dog Diseases; Dogs; Endometrial Hyperplasia; Epithelium; Female; Gene Expression; Growth Hormone; Immunohistochemistry; Medroxyprogesterone Acetate; Polymerase Chain Reaction; Progestins; RNA, Messenger; Uterus | 1997 |
The effect of medroxyprogesterone acetate on angiogenesis in complex endometrial hyperplasia.
Topics: Administration, Oral; Adult; Age Distribution; Aged; Antineoplastic Agents, Hormonal; Case-Control Studies; Endometrial Hyperplasia; Female; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Middle Aged; Neovascularization, Pathologic; Uterus | 1999 |
Apoptosis may be an early event of progestin therapy for endometrial hyperplasia.
Topics: Adult; Apoptosis; Cell Count; Endometrial Hyperplasia; Endometrium; Female; Humans; In Situ Nick-End Labeling; Medroxyprogesterone Acetate; Megestrol Acetate; Middle Aged; Paraffin Embedding; Progesterone Congeners; Progestins; Tumor Cells, Cultured | 2000 |
Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia.
Topics: Adolescent; Contraceptives, Oral, Synthetic; Cushing Syndrome; Endometrial Hyperplasia; Female; Glucocorticoids; Hormone Antagonists; Humans; Magnetic Resonance Imaging; Medroxyprogesterone Acetate; Mifepristone; Osteoporosis; Progesterone; Uterus | 2001 |
Conservative therapy for adenocarcinoma and atypical endometrial hyperplasia of the endometrium in young women: central pathologic review and treatment outcome.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Endometrial Neoplasms; Female; Fertility; Follow-Up Studies; Humans; Medroxyprogesterone Acetate; Pregnancy; Treatment Outcome | 2001 |
Organ preserving method in the management of atypical endometrial hyperplasia.
Topics: 17 alpha-Hydroxyprogesterone Caproate; Administration, Oral; Adult; Endometrial Hyperplasia; Female; Humans; Hydroxyprogesterones; Injections, Intramuscular; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Pregnancy; Progesterone Congeners | 2001 |
Treatment for complex atypical hyperplasia of the endometrium.
Topics: Adult; Antineoplastic Agents, Hormonal; Endometrial Hyperplasia; Female; Humans; Hysterectomy; Medroxyprogesterone Acetate; Middle Aged; Progesterone Congeners; Risk Factors; Treatment Outcome | 2001 |
[Diagnosis and treatment of endometrial hyperplasia].
Topics: ABO Blood-Group System; Adenocarcinoma; DNA Polymerase II; Endometrial Hyperplasia; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Oncogenes; Protein Biosynthesis; Receptors, Estrogen; Uterine Neoplasms | 1989 |
[Effect of long-term high-dose progesterone (Depo-Provera) therapy on endometrial carcinoma].
Topics: Aged; Carcinoma; Combined Modality Therapy; Dose-Response Relationship, Drug; Endometrial Hyperplasia; Endometrium; Female; Humans; Hysterectomy; Medroxyprogesterone; Medroxyprogesterone Acetate; Microscopy, Electron, Scanning; Preoperative Care; Uterine Neoplasms | 1985 |
[Medroxyprogesterone acetate in adenomatous hyperplasia of the uterine endometrium. Clinical and morphologic studies on the duration and dosage of gestagen therapy].
Topics: Adult; Dose-Response Relationship, Drug; Drug Administration Schedule; Endometrial Hyperplasia; Endometrium; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged | 1986 |
[Therapy with gestagens in hyperplastic changes of the endometrium].
Topics: Adenocarcinoma; Adenoma; Endometrial Hyperplasia; Endometrium; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Menstruation Disturbances; Norethindrone; Norethindrone Acetate; Uterine Neoplasms | 1986 |
Hormonal receptors in endometrial neoplasias.
Topics: Endometrial Hyperplasia; Female; Humans; Medroxyprogesterone; Medroxyprogesterone Acetate; Middle Aged; Prospective Studies; Receptors, Estradiol; Receptors, Progesterone; Tamoxifen; Uterine Neoplasms | 1988 |